BLA 125141 · Genzyme
Myozyme
Alglucosidase Alfa · Iv (Infusion)
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Feb 18, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Apr 28, 2006
Approved uses
1
Original approval plus efficacy supplements
Registered trials
30
6 Phase 3, 2 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 28, 2006 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
1 products under this application
- MYOZYME · ALGLUCOSIDASE ALFA 20MG/KG · INJECTABLE, IV (INFUSION) · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Alglucosidase Alfa" as an intervention, any sponsor and status, largest first.
- A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe DiseasePivotal-lookingCompleted
Amicus TherapeuticsIndustry
NCT03729362 · 125 participants · Start Dec 4, 2018 · Primary completion Dec 15, 2020
Drug: Cipaglucosidase Alfa; Miglustat and 2 more · For: Pompe Disease (Late-onset)
Sites: Phoenix, Arizona; Little Rock, Arkansas; Irvine, California · 73 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT01526785 · 113 participants · Start Mar 2012 · Primary completion Dec 2014
Drug: Alglucosidase alfa · For: Pompe Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 51 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT02782741 · 101 participants · Start Nov 2, 2016 · Primary completion Mar 19, 2020
Drug: Avalglucosidase alfa (GZ402666); Alglucosidase alfa (GZ419829) · For: Glycogen Storage Disease Type II;Pompe's Disease
Sites: Phoenix, Arizona; Los Angeles, California; Orange, California · 69 sites in all
- A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe DiseasePivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00158600 · 90 participants · Start Sep 2005 · Primary completion Sep 2007
Drug: alglucosidase alfa; Placebo · For: Pompe Disease (Late-onset); Glycogen Storage Disease Type II (GSD-II); Acid Maltase Deficiency Disease and 1 more
Sites: Beverly Hills, California; Washington D.C., District of Columbia; St Louis, Missouri · 8 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00455195 · 81 participants · Start Mar 2007 · Primary completion Oct 2008
Drug: alglucosidase alfa · For: Pompe Disease (Late-Onset); Glycogen Storage Disease Type II (GSD-II); Glycogenesis Type II and 1 more
Sites: Anchorage, Alaska; Phoenix, Arizona; Beverly Hills, California · 31 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT04676373 · 41 participants · Start Mar 10, 2021 · Primary completion Jul 25, 2024
Drug: ALGLUCOSIDASE ALFA · For: Pompe's Disease
Sites: China, China
- Drug-drug Interaction StudyCompleted
Amicus TherapeuticsIndustry
NCT01380743 · 25 participants · Start Oct 31, 2011 · Primary completion Jan 4, 2013
Drug: duvoglustat; rhGAA · For: Pompe Disease
Sites: Phoenix, Arizona; Scottsdale, Arizona; Orange, California · 15 sites in all
- Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.Completed
Genzyme, a Sanofi CompanySanofi (SNY)
NCT01898364 · 24 participants · Start Aug 19, 2013 · Primary completion Feb 25, 2015
Drug: GZ402666 · For: Pompe Disease; Glycogen Storage Disease Type II (GSD II); Acid Maltase Deficiency
Sites: Phoenix, Arizona; Jacksonville, Florida; Kansas City, Kansas · 17 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease.
Kishnani PS, Byrne BJ, Claeys KG, et al. · J Patient Rep Outcomes 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy.
Chen HA, Hsu RH, Fang CY, et al. · Front Immunol 2024 · Clinical Trial, Research Support, Non-U.S. Gov't
- Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
Diaz-Manera J, Kishnani PS, Kushlaf H, et al. · Lancet Neurol 2021 · Multicenter Study, Randomized Controlled Trial
- Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
Schoser B, Roberts M, Byrne BJ, et al. · Lancet Neurol 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial.
Kishnani PS, Diaz-Manera J, Toscano A, et al. · JAMA Neurol 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- The Mini-COMET Clinical Trial: Safety and Efficacy of Avalglucosidase Alfa after 97 Weeks of Treatment in Children with Infantile-Onset Pompe Disease Previously Treated with Alglucosidase Alfa.
Kronn D, Davison J, Broomfield A, et al. · J Pediatr 2025 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.